Finalist
Langland Medical Strategy and Education (MSE)
Summary of work
After a successful 2023, the 2024 approach was to continue this trajectory, building on the enduring momentum and advancement of medical affairs and evolving to meet changing client needs. Our strategy focused on 3 pillars for success: leadership through scientific strategy capabilities, targeted business development and evolution of our AI capabilities. Supported by our proprietary “Think Further” model and a team who live and breathe the core values of discipline, imagination and togetherness we remained laser focused throughout 2024. We partnered with four separate clients for four diverse projects demonstrating the potential impact of Gen AI in creating both efficiencies in content development and adding value to healthcare stakeholder engagement. Our scientific strategy division continues be a cornerstone in our long-standing strategic partnerships and a shift in resource alignment unlocked additional capacity within the division to strengthen and expand our strategic partnerships with adding value across the drug development life cycle, across geographic designations and across large and mid-sized pharma. These efforts led to tangible results: maintaining high staff retention and engagement; securing new business through client referrals and organic opportunities; delivering market shaping programmes; and achieving continued growth year-on-year, doubling in size since 2020.
Judges’ comments
The Langland MSE team did a good presentation and touched on some important issues. They had a clear plan for growth from organic, cross agency and through AI, and it all seems to be working. They highlighted with honesty the challenges faced and how they overcame them.
